Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma

NCT02743429 is registered in ClinicalTrials.gov with University Medicine Greifswald as lead sponsor.

NCT NCT02743429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02743429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
Lead sponsor
University Medicine Greifswald
Phase
Phase 2
Overall status
Unknown status
Start date
March 27, 2015
Completion date
June 30, 2024
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma